Roslin Russell, Protein Logic, Cambridge, UK
One industrial Partner (PLOGIC; P6), is engaged in biomarker discovery and exploitation, developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection. PLOGIC is developing biomarker panels for CLL cancer and will contribute assay development and analytical expertise to this project.
Protein logic (PLOGIC), ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. This technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.
Major research activities at Protein logic include the development and application of the ImmiPrint® diagnostic technology, which allows the rapid screening of large CD panels, thereby facilitating effective disease-specific CD panel development. This unique technology enables the multiplexed quantitative CD assays, screening up to 60 CDs from a single sample. This research on new diagnostic technologies is tight in with Bioinformatics research to optimally use sCD data for clinical diagnoses and to combine these data with other omcis assays. PLOGIC has already derived predictive CD signatures for more than 14 different disease areas, including CLL and breast cancer, which will be used and extended within this project. PLOGIC is actively collaborating with researchers at leading academic institutions, including the European Bioinformatics Institute, Kings College London and Cancer Research UK.
W1: P6 will contribute to the development of the integrated analysis framework, ensuring that sCD data can be handled within the system. Specifically, P6 will extend the eDIVA platform to handle molecular phenotypes, in particular readouts from sCD platforms.
W6: P6 will lead the work package, perform biomarker development work, analysis and integration of the biomarker readouts with genomics data obtained. To do so, P6 will also develop new computational methods to aid the design of sCD panels and the analysis of sCD data in conjunction wither other omics data.
Roslin Russell has extensive experience in analysing and handling high-throughput genomics (microarray & HTP sequencing; both DNA & RNA) and more recently, in proteomics mass spectrometry data (SiLAC, iTRAQ & Tandem Mass Tags). She is involved in METABRIC (Molecular Taxonomy of Breast Cancer International Consortium), a cohort of 2000 breast cancer samples from both the UK and Canada, and also CamCap, a cohort of 300 prostate cancer samples from both the UK and the Karolinska Institute, Sweden.
Roslin Russell (female, PhD) received her doctorate in Molecular Biology from the University of Cambridge in the UK. She specialises in analysing high throughput genomics and proteomics data in cancer, with the aim of classifying tumours and discovering biomarkers. She is currently a Senior Research Fellow and Computational Biologist at the Cancer Research UK, Cambridge Institute and working for Protein Logic as senior Bioinformatician for more than 3 years. If this proposal gest funded, Dr. Russell will move onto a full time position at Protein Logic, leading the Bioinformatics development.
Keith Burling (male, MSC). Director of the Core Biochemical Assay Laboratory at Addenbrookes Hospital Cambridge. Keith is leading the assay development for Protein Logic and will oversee sCD data production
Protein Logic has established an infrastructure to develop and apply CD antigen panels to large cohorts. In the context of this project, PLOGIC will supply assay development work and assay design. The company has extensive IP for both the design and test of sCD-panels, and for the Bioinformatics-based analyses.
